Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab

Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab

Abstract Background Tremelimumab is an antibody that blocks CTLA-4 and demonstrates clinical efficacy in a subset of advanced melanoma patients. An unmet clinical need exists for blood-based response-predictive gene signatures to facilitate clinically effective and cost-efficient use of such immunot...

Full description

Bibliographic Details
Main Authors: Philip Friedlander, Karl Wassmann, Alan M. Christenfeld, David Fisher, Chrisann Kyi, John M. Kirkwood, Nina Bhardwaj, William K. Oh
Format: Article
Language:English
Published: BMJ Publishing Group 2017-08-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Melanoma
Biomarker
Tremelimumab
CTLA-4
Predictive
Online Access:http://link.springer.com/article/10.1186/s40425-017-0272-z

Internet

http://link.springer.com/article/10.1186/s40425-017-0272-z

Similar Items